For medical professionals

Referrals and consultation

About referrals and consultation at Children’s

Children’s asthma, allergy and immunology program provides referrals and consultation for children and adults.

  • For consults, referrals and transport, call our Physician Call Center at (414) 266-2460 or toll free at (800) 266-0366.
  • For outpatient specialty appointments, call Central Scheduling at (414) 607-5280 or toll-free (877) 607-5280

Read more

Asthma, allergy and immunology fellowships

The Allergy-Immunology Fellowship Program

The allergy and immunology (AI) fellowship program trains future academicians and leaders in the field of AI. We accept physicians with backgrounds in internal medicine or pediatrics in the field of allergy and clinical Immunology.

As the allergy/immunology service for the Medical College of Wisconsin, we service Children's Hospital of Wisconsin, Froedtert Memorial Lutheran Hospital, and Veterans Administration Medical Center.

Research

A new testing program for SCID in newborns

Children's Hospital and the Wisconsin State Laboratory of Hygiene lead the nation and made Wisconsin the first state to pilot a newborn screening test for severe combined immunodeficiency. The test identifies SCID early enough to help treat children impacted by this often fatal disease.

The Clinical Immunodiagnostic and Research Laboratory (CIRL)

A joint effort between Children's Hospital of Wisconsin and the Medical College of Wisconsin, the CIRL combines academic, scientific and technical strengths to provide state-of-the-art clinical and research procedures. A complete list of test descriptions and order forms can be found on the page for Clinical Flow Cytometry in the Diagnosis of Primary Immunodeficiencies.

Our team develops and performs specialized tests using patient samples from around the world. We are dedicated to working with Children’s physicians to provide the best patient care in a research context. In addition, our clients include local, regional, and nation laboratories, as well as pharmaceutical companies and physician practices.

Current Research

Our ongoing clinical research projects in the area of food allergies include:

  • Detection of peanut protein in serum and saliva
  • Determination of minimum and non-provoking doses of soy protein in soy allergic individuals
  • At home food challenges with egg allergic patients, prospective study

Our research in the area of primary Immunodeficiency includes:

  • Newborn screening for severe combined immune deficiency (SCID) in Wisconsin: The purpose of this research is to develop a collaborative program with the WI State Department of Hygiene to screen all newborns in the State of WI for SCID. We will extract DNA from blood spots on newborn screening cards and use real time PCR to quantitate T cell receptor circles to screen for SCID.
  • Lymphoproliferative disorders in primary immunodeficiencies: the purpose of this research is to determine if transforming viral infections leads to lymphoproliferative disorders in patients with primary immune deficiencies.
  • CD49d expressing neutrophils differentiate atopic from non-atopic individuals
  • IgE against human rhinovirus

Current Trials

Children’s is currently conducting or participating in the following pediatric and adult asthma trials:

  • Phase IIIb Multi-center, Randomized, Double-Blind, Placebo-Controlled Study of Xolair® in Subjects with Moderate to Severe Persistent Asthma Who are Inadequately Controlled With High-Dose Inhaled Corticosteroids and Long-Acting Beta-Agonist
  • Epidemiologic Study of Xolair® (Omalizumab): Evaluating Clinical Effectiveness and Long-Term Safety in Patients With Moderate to Severe Asthma (EXCELS)
  • A One Year, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Multicenter Evaluation of Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Omalizumab in Children (6 - <12 years) With Moderate-Severe, Persistent, Inadequately Controlled Allergic Asthma.
  • Study of Acid Reflux in Children with Asthma (SARCA): The purpose of this NIH-funded research is to test the hypothesis that children with symptomatic asthma will have improved asthma control with medical treatment of esophageal reflux with the proton-pump inhibitor, lansoprazole, as compared to children treated with placebo.